18:51 , Mar 29, 2019 |  BC Week In Review  |  Clinical News

Alkahest’s AKST4290 improves visual acuity in Phase IIa for AMD

Alkahest said AKST4290 led to a mean improvement of 7 letters in best corrected visual acuity (BCVA) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart from baseline to week six in...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
00:47 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Mouse studies suggest inhibiting IL5Rα or CCR3 could help treat intestinal fibrosis caused by abdominal radiation therapy. In a mouse model of abdominal radiation-induced intestinal fibrosis, a mAb targeting IL5Rα, a tool compound...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 7 (CCL7; MCP3; SCYA6); CC chemokine receptor 3 (CCR3; CD193)

Cancer INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting CCL7- CCR3 signaling could help treat prostate cancer. In patients with prostate cancer, tumor levels of CCR3 correlated with disease recurrence or...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

LeukoSite other research news

LKST and collaborators published in Science the identity of a chemokine receptor that targets Type 2 T helper cells to tissues involved in an allergic response. The migratory pattern of the different types of T...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

ASM8: Phase IIa data

The double-blind, 3-way crossover, Canadian Phase IIa TPI ASM8-207 trial in 16 patients with allergic asthma showed that once-daily 3 and 7.8 mg inhaled ASM8 administered via a nebulizer significantly reduced allergen-induced LAR from baseline...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

ASM8: Completed Phase II enrollment

Pharmaxis completed enrollment of 16 adult asthmatics in a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial evaluating once-daily 3 and 7.8 mg ASM8 for 14 days. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia  ...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

ASM8: Phase II started

Pharmaxis began a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial in 16 adult asthmatics to evaluate once-daily 3 and 7.8 mg ASM8 for 14 days. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia   Product:...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche 's Genentech Inc. unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease. 1 Nineteen of the 112 candidate...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Clinical News

ASM8: Phase IIa data

In the open-label, Canadian Phase IIa TPI ASM8-206 trial in 12 patients, inhaled 8 mg ASM8 once daily for 4 days met the primary endpoint of significantly reducing sputum eosinophil count at 7 and 24...